As reldesemtiv has a distinctly different mechanism of action compared to currently available therapies for SMA that increase levels of the SMN protein, in a future reldesemtiv trial, we anticipate including eligibility criteria permitting current or past use of such medicines with enrolled patients stratified accordingly. Here, SMN2 is linked to proximal spinal muscular atrophy.